Brain Cancer — Expert Neurosurgical, Neuro-Oncology & Advanced Therapy Access

The most common early symptoms of brain cancer depend on tumor location but frequently include: new-onset headaches (particularly worse in the morning or disrupting sleep), new seizures in an adult with no prior epilepsy history, gradual changes in cognitive function or personality, and focal neurological symptoms such as weakness, numbness, or speech difficulty on one side of the body. Visual changes or coordination problems may also occur. The combination of progressive neurological symptoms and raised intracranial pressure features (morning headache, nausea, vomiting) should prompt urgent brain MRI.

Glioblastoma (GBM), formally called Glioblastoma IDH-wildtype WHO Grade 4, is the most common and most aggressive primary malignant brain tumor in adults. It is defined by its IDH-wildtype molecular status combined with histological features of necrosis, microvascular proliferation, and rapid growth. Unlike IDH-mutant gliomas (astrocytomas and oligodendrogliomas, which carry more favorable prognoses), GBM is highly aggressive. The current standard treatment involves surgical resection followed by concurrent chemoradiation with temozolomide and then adjuvant temozolomide, plus tumor treating fields (TTFields) — but the disease almost always recurs.

IDH (Isocitrate Dehydrogenase) mutations — most commonly IDH1 R132H — are early driver mutations found in the majority of lower-grade gliomas (astrocytomas and oligodendrogliomas) and a subset of Grade 4 gliomas. They are the single most important prognostic molecular marker in glioma biology. IDH-mutant gliomas behave significantly less aggressively than IDH-wildtype tumors, even when histologically identical. Vorasidenib, a brain-penetrant IDH1/2 inhibitor, was recently approved for WHO Grade 2 IDH-mutant glioma and represents the first targeted therapy approved for this patient group.

MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme that can repair DNA damage caused by alkylating chemotherapy drugs like temozolomide. When the MGMT gene's promoter region is methylated (silenced by epigenetic modification), the MGMT enzyme is not produced, and the tumor cells cannot repair temozolomide-induced DNA damage as effectively — making them more sensitive to temozolomide. Patients with MGMT-methylated GBM benefit significantly more from temozolomide chemotherapy than those with unmethylated tumors. MGMT status is now tested in all newly diagnosed GBM patients.

Tumor Treating Fields (TTFields) are a form of electric field therapy delivered through transducer arrays worn on the shaved scalp. The device (Optune) delivers low-intensity, alternating electric fields at an intermediate frequency that disrupts the mitotic spindle during cell division, selectively killing rapidly dividing tumor cells. In the EF-14 clinical trial, TTFields combined with temozolomide after chemoradiation improved overall survival in newly diagnosed GBM compared to temozolomide alone. Compliance is key — patients who wear the device for more than 18 hours per day have better outcomes. TTFields are approved by the FDA for newly diagnosed and recurrent GBM.

Surgical resection of brain tumors is one of the most technically demanding areas of surgery, and the goal is to achieve the maximum possible tumor removal while preserving neurological function. Modern techniques that help achieve this include awake craniotomy with cortical and subcortical mapping (the patient remains awake during tumor removal, allowing real-time assessment of speech and motor function), intraoperative MRI (which allows the surgeon to see any remaining tumor during surgery), fluorescence-guided surgery using 5-ALA (which makes GBM cells glow under blue light), and neuronavigation systems. These techniques have significantly expanded the extent of safely achievable resection and improved outcomes.

Brain cancer — particularly GBM — has one of the most active clinical trial landscapes in oncology. Currently recruiting trials include CAR-T cell therapies targeting EGFRvIII, IL13Rα2, GD2, and B7-H3; ONC201 (for H3K27M-mutant diffuse midline glioma); personalized neoantigen vaccines; oncolytic virus therapies; immunotherapy combinations (pembrolizumab or nivolumab with chemotherapy or TTFields); BRAF + MEK inhibition for BRAF V600E-mutant gliomas; and novel focused ultrasound blood-brain barrier opening approaches to improve drug delivery. CancerFax can assist in identifying trials relevant to a patient's specific tumor molecular profile and connecting them with participating centers internationally.

Post-treatment surveillance uses serial MRI brain with gadolinium contrast — typically every 2–3 months during active treatment and for the first 2 years after completion of radiotherapy, then every 3–6 months. A critical challenge is distinguishing true tumor recurrence from pseudoprogression — apparent worsening on MRI that is actually a treatment effect from inflammation, not tumor growth. Pseudoprogression occurs in approximately 20–30% of GBM patients, especially those with MGMT methylation, and can resolve without treatment change. Advanced MRI techniques (perfusion imaging, MR spectroscopy) and PET scans help differentiate pseudoprogression from true recurrence.

Yes. CancerFax provides comprehensive specialist support for patients with all types of brain cancer — from GBM to lower-grade IDH-mutant gliomas, ependymomas, and diffuse midline gliomas. We review MRI reports, surgical pathology, molecular profiling (IDH, MGMT, 1p/19q, TERT, H3K27M), and treatment history, then connect patients with specialist neuro-oncologists and neurosurgeons internationally — including in India, Germany, South Korea, and the UAE, where expert brain tumor centers offer awake craniotomy, TTFields, proton therapy, and clinical trial access. We assist with second opinions, resectability assessments, molecular profiling guidance, TTFields access coordination, and trial enrollment support.